| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 28/01/2025 | 22:10 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 27/01/2025 | 22:27 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 13/01/2025 | 14:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 13/01/2025 | 14:05 | Business Wire | Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 18/12/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 03/12/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 21/11/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 31/10/2024 | 21:39 | Edgar (US Regulatory) | Form 424B7 - Prospectus [Rule 424(b)(7)] | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 31/10/2024 | 03:30 | PR Newswire (US) | Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 29/10/2024 | 22:15 | PR Newswire (US) | Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 29/10/2024 | 13:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 29/10/2024 | 12:30 | PR Newswire (US) | HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 16/10/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024 | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 01/10/2024 | 14:45 | PR Newswire (US) | HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 26/09/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024 | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 06/08/2024 | 13:30 | GlobeNewswire Inc. | Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028 | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 23/07/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024 | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 25/06/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 24/06/2024 | 13:00 | PR Newswire (US) | HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 05/06/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1 | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 28/05/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 30/04/2024 | 13:05 | GlobeNewswire Inc. | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 30/04/2024 | 13:00 | PR Newswire (US) | Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 16/04/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 11/04/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 03/04/2024 | 14:05 | PR Newswire (US) | HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 26/03/2024 | 13:05 | PR Newswire (US) | HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 28/02/2024 | 23:16 | Edgar (US Regulatory) | Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 22/02/2024 | 22:14 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
| 22/02/2024 | 14:00 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:HRMY | Harmony Biosciences Holdings Inc |
